Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04389294 · ClinicalTrials.gov registry record · NA
HSS Covid-19 Antibody Serology Among Surgeons & Anesthesiologists
A NA study of COVID, sponsored by Hospital for Special Surgery, New York.
- Completed
- Registry status
- NA
- Development phase
- 143
- Enrollment target
- 1
- Study location
NCT04389294: Completed NA study of COVID, sponsored by Hospital for Special Surgery, New York.
NCT04389294 is a NA study of COVID that has completed, run by Hospital for Special Surgery, New York. The registered enrollment target is 143 participants, below the 2,593-participant average among 14 other COVID trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04389294, a NA study of COVID, has completed, sponsored by Hospital for Special Surgery, New York.
- COMPLETED
- Registry status
- NA
- Development phase
- 143 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to understand the infectious exposure of SARS-coronavirus 2 (SARS-CoV2) among surgeons and anesthesiologists and to correlate this status with self-reported indices of COVID-19 illness.
Primary Outcome
Prevalence of SARS-CoV-2 IgG antibodies by serology testing in participants at the time of study enrollment or 3 months later
Conditions Studied
Interventions
- DIAGNOSTIC_TEST SARS-CoV2 serum antibody testing
Study Locations (1)
New York
- Hospital for Special Surgery - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 143 participants |
| Start Date | 2020-05-05 |
| Est. Completion | 2020-09-04 |
| Phase | NA |
What the finished NCT04389294 record still lists
NCT04389294 is an interventional study that assigns participants to a tested intervention. The registered 143 participants enrollment target is mid-sized for trials with a published cap, below the 2,593-participant average among 14 other COVID trials with a reported enrollment target (94% lower).
The record links to 1 condition, with COVID appearing as the primary indexed condition, and to 1 intervention - of which SARS-CoV2 serum antibody testing is the first listed.
NCT04389294 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT04389294 about?
NCT04389294 is a clinical study titled "HSS Covid-19 Antibody Serology Among Surgeons & Anesthesiologists". The goal of this study is to understand the infectious exposure of SARS-coronavirus 2 (SARS-CoV2) among surgeons and anesthesiologists and to correlate this status with self-reported indices of COVID-19 illness.
What is the current status of trial NCT04389294?
This trial is currently completed. It is a NA study. The enrollment target is 143 participants. The study started on 2020-05-05. Estimated completion is 2020-09-04.
What conditions does trial NCT04389294 study?
This clinical trial studies the following conditions: COVID.
What interventions are being tested in trial NCT04389294?
The interventions under investigation include: SARS-CoV2 serum antibody testing (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04389294?
This trial is sponsored by Hospital for Special Surgery, New York, which has 194 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04389294 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04389294's enrollment target sits among peer trials
143 12th of 14 higher than 3 of 14 other COVID trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Clinical Validation of the Aptitude Medical Systems Metrix COVID-19 Test
RECRUITING · NA
-
Prospective Clinical Evaluation of the BioFire Emerging Coronavirus Panel for the Detection of COVID-19 and Other Coronaviruses
RECRUITING
-
Long-term Impact of Infection With Novel Coronavirus (COVID-19)
RECRUITING
-
Outpatient Treatment With Anti-Coronavirus Immunoglobulin
RECRUITING · Phase 3
-
A Study to Explore the Role of Gut Flora in COVID-19 Infection
RECRUITING
-
COVID-19 Biorepository
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01861106 · 144 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
- NCT03482245 · 144 participants · NA
The Role of Circadian Clock Proteins in Innate and Adaptive Immunity
- NCT03504683 · 144 participants · NA
MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes
- NCT03905603 · 144 participants · Early Phase 1
Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI